

# Study to derive a final lead candidate of TCR-T cell therapy for the treatment of EGFR L858R mutant lung cancer patients

DAAN Biotherapeutics



ONCOLOGY	Candidate
Product Type	TCR-T Cell Therapy
Indication	Solid tumor
Target	EGFR mutant neoantigen (peptide-MHC)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>Targeting tumor specific neoantigen (peptide-MHC)</li> <li>Engineering patient-derived CD8+ T cells by replacing endogenous TCR with exogenous potent TCRs</li> <li>Enhancing cytotoxic T-cell's tumor microenvironment (TME) infiltration and T-cell stemness by T-cell engineering with proprietary switch receptor and cytokines</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>DAAN Biotherapeutics TCR-T cell therapy targets an oncogenic driver mutation, EGFR-mutation, which is highly tumor specific, minimizing non-target toxicity for clinical development</li> <li>TARGET platform discovers novel TCRs recognizing neoantigens (peptide-MHC), as well as tumor-specific and tumor-associate antigens from patients' tumor tissues</li> <li>Proprietary TCR-T cell therapy platform, which includes switch receptor and engineered cytokine, enhances anti-tumor efficacy by improving cytotoxic T-cell's TME infiltration and T-cell memory functions</li> </ul>
Development Stage	Candidate
Route of Administration	Ex vivo TCR gene/cell engineering – intravenous injection